Table 2 Descriptive analysis of four clinical outcomes for participants in the Godelieve Denys-Struyf (GDS) arm and treatment as usual (TAU) arm with data at baseline and 4-month follow-up
Outcomes | Baseline | 4-month follow-up | Mean difference between groups, GDS vs TAU (95% CI)d | ||
|---|---|---|---|---|---|
GDS (n = 15) | TAU (n = 14) | GDS | TAU | ||
ODIa (0–100), mean (SD) | 32.9 (11.0) | 35.6 (11.4) | 24.3 (12.5) | 38.6 (14.5) | -13.1 (-22.2 to -3.9) |
Median (IQR) | 30 (10) | 36 (16) | 24 (22) | 36 (25) | |
Back painb (0–100), mean (SD) | 63.1 (14.2) | 53.0 (17.3) | 33.6 (24.5) | 59.7 (23.8) | -33.9 (-50.7 to -17.0) |
Median (IQR) | 70 (20) | 50 (30) | 40 (49) | 70 (35) | |
Leg painb (0–100), mean (SD) | 69.0 (13.8) | 48.7 (22.3) | 35.5 (26.7) | 58.6 (24.5) | -37-0 (-56.1 to -18.0) |
Median (IQR) | 70 (19) | 50 (40) | 20 (55) | 60 (33) | |
EQ5D-5Lc, mean (SD) | 0.63 (0.22) | 0.61 (0.25) | 0.73 (0.13) | 0.58 (0.29) | -0.14 (-0.31 to 0.03) |
Median (IQR) | 0.73 (0.40) | 0.73 (0.67) | 0.75 (0.22) | 0.68 (0.47) | |